scholarly journals Safety and outcome of external beam radiation and neutron brachytherapy in elderly patients with esophageal squamous cell cancer

2017 ◽  
Vol 1 ◽  
pp. 34-43 ◽  
Author(s):  
Tao Li ◽  
Wei Zhang ◽  
Jiahua Lv ◽  
Huiming Liu ◽  
Qifeng Wang ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Neutron Brachytherapy

Prognostic value of systemic immune-inflammation index in elderly patients with esophageal squamous cell cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15500-e15500
Author(s):  
Shengjun Ji ◽  
Qingqing Chen
Keyword(s):  
Elderly Patients ◽  
Squamous Cell ◽  
Roc Curve ◽  
Squamous Cell Cancer ◽  
Univariate Analysis ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Optimal Threshold ◽  
Predictive Index ◽  
N Stage

e15500 Background: The aim is to assess the value of systemic immune-infflammation index (SII) in elderly patients with esophageal squamous cell cancer after radiotherapy. Methods: Total 128 patients larger than 65 years were included. The optimal threshold of SII was determined by establishing a receiver operating characteristic (ROC) curve, and the relationship between SII and prognosis was analyzed. Results: The ROC curve showed that the optimal threshold of the pretherapeutic SII for predicting the efficacy of radiotherapy was 700.97. Univariate analysis showed that SII was significantly associated with radiotherapy (P<0.001). The OS of the low SII group was 83.5%, 62.0%, 48.1% for 1 year, 2 years, and 3 years, respectively. The OS of the high SII group was 75.5%, 30.6%, 24.5% for 1 year, 2 years, and 3 years, respectively. The differences were statistically significant (all P<0.001). Univariate analysis showed that SII, N stage, and TNM stage were all related to the OS (all P < 0.01). Cox multivariate analysis showed that SII were independent prognostic factors. Conclusions: SII is a predictive index for elderly patients with esophageal squamous cell cancer after radiotherapy.

Nonoperative therapy for squamous-cell cancer of the esophagus.

1987 ◽  
Vol 5 (3) ◽  
pp. 365-370 ◽  
Author(s):  
L Leichman ◽  
A Herskovic ◽  
C G Leichman ◽  
P B Lattin ◽  
Z Steiger ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Pilot Trial ◽  
Drug Regimen ◽  
Distant Recurrence ◽  
External Beam Radiation ◽  
Barium Swallow ◽  
Beam Radiation

Based on the surgical pathology and survival for patients in previous trials using a neoadjuvant program of chemotherapy (5-fluorouracil [5-FU]-cisplatin) and radiation (3,000 cGy) before surgery for squamous-cell cancer (SCC) of the esophagus, a nonoperative pilot trial was designed to test if survival and recurrence would differ from our historical controls if routine esophagectomy was eliminated. Twenty patients were treated. The protocol called for the delivery of 5-FU infusion (1,000 mg/m2/d X 4 d) days 1 to 4 and 29 to 32 with cisplatin (100 mg/m2) day 1 and 29 sandwiched around external beam radiation (3,000 cGy over 3 weeks). Mitomycin C (10 mg/m2) day 57 was administered with bleomycin infusion (20 U/d X 4 d) days 57 to 60 and 78 to 81. A radiation boost of 2,000 cGy was administered 200 cGy/d days 99 to 103 and 106 to 110. Clinical pulmonary toxicity forced withdrawal of bleomycin and mitomycin C in the last four patients treated; two further courses of 5-FU-cisplatin were administered instead. The median measurement of the 20 esophageal lesions by barium swallow was 7 cm. Four patients underwent salvage surgery to prevent life-threatening aspiration pneumonia. The median survival for the 20 patients is 22 months, with a range from 6 to 39+ months. The six patients clinically without cancer are alive 22+ to 39+ months (median, 35+ months). Three patients died manifesting only local (infield) recurrence; five died manifesting only distant recurrence; and five developed local and distant recurrence. While the toxicity of the four drug regimen as administered was prohibitive, the survival and quality of survival is superior to the regimen previously used, which routinely used surgery after preoperative chemotherapy and radiation.

Sign in / Sign up

Export Citation Format

Share Document